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Abstract
Purpose: The purpose of this study was to evaluate magnetic resonance imaging (MRI)-pathology concordance of 
tumour size in patients with invasive breast carcinoma, with an emphasis on Breast Imaging Reporting and Data 
System (BI-RADS) descriptors of dynamic contrast-enhanced MRI (DCE-MRI).
Material and methods: Of patients who had preoperative DCE-MRI, 94 were enrolled. Concordance between MRI 
and the pathological findings was defined as a difference in tumour size of 5 mm or less. The greatest dimension 
was measured by two radiologists, and BI-RADS descriptives were described in accordance. The gold standard was 
chosen as the pathologic assessment.
Results: Tumour measurements determined by MRI and the pathological reports were not statistically different (2.64 
± 1.16 cm, Wilcaxon Z = –1.853, p = 0.064). Tumour sizes were concordant in 72/94 patients (76.6%). The mean 
difference between the pathological and MRI tumour sizes was –0.1 cm. MRI overestimated the size of 17/94 tumours 
(18.1%) and underestimated the size of 5/94 tumours (5.3%). Discordance was associated with larger tumour size. 
Histologic and molecular type of tumours, patient age, histologic grade, lymphovascular invasion or perineural in-
vasion positivity, fibroglandular volume, background parenchymal enhancement, and being mass or non-mass were 
not associated with concordance. Irregular margin and heterogenous enhancement in DCE-MRI were associated 
with discordance in logistic regression analysis (p = 0.035, OR: 4.24; p = 0.021, OR: 4.96). 
Conclusions: Two BI-RADS descriptors of irregular contour and heterogeneous contrast uptake were found to be 
associated with tumour size discrepancy. This might be attributed to the dynamic and morphologic specialities of 
tumours primarily rather than tumour biology.
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Introduction
Tumour size is the main component of cancer staging, 
which guides correct therapeutic decision making. A precise 
assessment of maximum tumour size is essential for choos-
ing the surgery plan for breast conservation or mastectomy. 
Complete excision of the tumour foci is the primary goal be-
cause it prevents tumour recurrence [1,2]. Furthermore, it is 
important for oncologists to determine tumour size because 
it relates to primary systemic therapy [3]. It might also be 
related to the cosmetic outcome [4].
Dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI) is shown to be more precise than 
ultrasound (US) or mammography (MG) for estimating 
tumour size, local extent, and additional foci of breast 
carcinoma [5]. Also, accuracy in estimating preoperative 
tumour size with the use of clinical breast examination 
(CBE), US, MG, and DCE-MRI, has been studied in the 
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literature, and CBE, MG, and DCE-MRI are more likely to 
overestimate the size, whereas US mostly underestimates 
it [6-8]. Whichever of the aforementioned modalities were 
used, the Breast Imaging-Reporting and Data System 
(BI-RADS) of the American College of Radiology (ACR) 
is essential for patient analysis. BI-RADS includes imag-
ing findings, assessments, and recommendations for ra-
diologists and physicians. The first edition of the BI-RADS 
atlas published in 1992 was limited to mammography. 
Since the fourth edition of BI-RADS, MRI descriptives 
were added to score the likelihood of malignancy [9]. 
It depends on morphologic and dynamic findings, which 
include moderate to substantial agreement in interobserv-
er assessments [10].
The factors affecting discordance between DCE-MRI 
and histopathologic tumour size measurements have 
been investigated previously [2,4-8,11-14]. Although the 
presence of ductal carcinoma in situ (DCIS), non-mass 
enhancement in DCE-MRI, and oestrogen receptor pos-
itivity have been found to be related with overestimation, 
the BI-RADS descriptives have not found the right place, 
in our opinion. Our aim was to evaluate MRI-pathology 
concordance of tumour size measurements in patients 
with invasive breast carcinoma with emphasis on BI-
RADS descriptors of DCE-MRI.
Material and methods
Methods
This retrospective study was approved by the Institutional 
Review Board at our university hospital. All procedures 
were conducted in accordance with the Declaration of 
Helsinki. The requirement for informed consent was 
waived because of the study design. 
Patient cohort
A retrospective analysis of the medical records of patients 
with surgically confirmed breast carcinoma, who were 
treated at our institution between January 2017 and Au-
gust 2018, was conducted. We excluded those who under-
went neoadjuvant chemotherapy, those who underwent 
excisional biopsy before breast MRI, and those who did 
not have pathologic data such as the nuclear grade, histo-
logic grade, or HER2 status. Also, patients with DCIS, an 
invasive cancer with an extensive intraductal component, 
whose tumours were re-excised were excluded because of 
the potentially problematic nature of determining an ac-
curate pathologic size [15,16]. A total of 94 patients were 
enrolled in the study.
Breast DCE-MRI protocol
Written, informed consent was obtained from all patients 
before DCE-MRI. All breast DCE-MRIs were performed 
using a 3T scanner (Verio, Siemens Healthcare, Erlan-
gen, Germany) with a phase-array eight-channel bilater-
al breast receive coil (Breastmatrix, Siemens Healthcare, 
Erlangen, Germany). An intravenous catheter was insert-
ed into the antecubital vein of the left or right arm before 
the examination. Each study included unenhanced non–
fat-saturated T1-weighted and fat-saturated T2-weight-
ed sequences. Axial turbo-spin echo inversion recovery 
fat-saturated T2-weighted sequences were performed 
using the following parameters: TR = 3000-3500 ms, TE 
= 79 ms, field of view (FOV) = 20-24 cm, matrix = 288 
x 192, slice thickness = 4 mm with no gap, flip angle = 
90 degrees, and number of excitations (NEX) = 2. Then, 
dynamic contrast-enhanced sequences containing axial 
T1-weighted three-dimensional (3D) fast spoiled gra-
dient recall echo sequences (TR = 5.3, TE = 2.5, FOV = 
20-24 cm, matrix = 256 x 256, slice thickness = 4 mm) 
were performed. DCE-MRI included one precontrast 
acquisition and five postcontrast acquisitions after the 
injection of gadolinium-diethylene triamine pentacetate 
acid (Magnevist; Bayer HealthCare, Wayne, NJ). Contrast 
was injected at a dose of 0.1 mmol/kg body weight using 
an automated pump (Nemoto; Nemoto Kyorindo, Tokyo, 
Japan) followed by a 20 ml saline flush, both at a rate of 
2 ml/s. Standard subtraction images and time-resolved 
transversal maximum intensity projection (MIP) of the 
subtraction images of both breasts were created. All MRI 
examinations were performed between seven and 14 days 
of the menstrual cycle to minimise enhancement of nor-
mal glandular tissue.
Image analysis
All images were assessed retrospectively by two radi-
ologists with experience in breast MRI interpretation 
(A.A.G: two years’ experience, E.I: five years’ experience). 
The greatest dimension was measured using an electronic 
digital calliper. Concordance between MRI and the final 
pathology results were defined as a difference in tumour 
size of ≤ 5 mm.
Early-subtracted DCE T1W sequence was used for tu-
mour size measurements. Tumour morphology, DCE ki-
netics, and multiplicity were analysed based on the second 
edition of BI-RADS [17]. Lesions were classified as mass or 
non-mass enhancement lesions. Mass is a three-dimension-
al lesion that occupies a space within the breast. Non-mass 
enhancements are areas of enhancement without a detect-
able three-dimensional margin. The shape (oval, round, or 
irregular), margin (circumscribed, irregular, or spiculated), 
and internal enhancement characteristics (homogeneous, 
heterogeneous, rim enhancement, or dark internal sep-
tations) of a mass lesion were evaluated. MR Syngo Sta-
tion (Siemens Healthcare, Erlangen, Germany) was used 
to generate colour-coded information on lesion kinetics. 
The time-intensity curves were assessed based on delayed 
phases. The delayed phase was categorised into three types: 
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type 1, persistent; type 2, plateau; or type 3, washout. Mul-
tiplicity was defined as the presence of more than one un-
connected breast lesion. When there were multiple lesions 
in a breast, the largest lesion alone was analysed. 
The level of background parenchymal enhancement 
(BPE) was visually and subjectively assessed across the 
entire breast parenchyma. Maximum-intensity projection 
images were used to evaluate BPE, which is classified as 
minimal, mild, moderate, or marked according to the 
percentage of enhanced glandular tissue (< 25%, 25-50%, 
50-75%, and > 75%, respectively). Women were then as-
signed to two different groups, depending on the degree 
of BPE. Group 1 consisted of women with minimal or 
mild BPE, and group 2 consisted of women with moder-
ate or marked BPE. Also, fibroglandular volume (FGV) 
was analysed qualitatively by evaluating T1-weighted im-
ages, and categorisations were done by using the fourth 
edition of ACR BI-RADS according to the percentage 
of glandular tissue. We categorised the breast density as 
dens or non-dense. The dense category was defined for 
VDG 3 and 4, and non-dense breasts were classified as 
VDG 1 and 2.
Pathologic analysis
All patients’ medical records were compiled. Pathologi-
cal reports of breast-conserving surgery or mastectomy 
specimens were reviewed to determine the tumour type, 
maximum diameter of the invasive tumour, histological 
grade, lymphovascular invasion, and perineural inva-
sion. Consistent with the common practice of the pa-
thology service of our institution, all histological exami-
nations were performed according to generally accepted 
standards [18]. Palpable tumours were sliced in the long 
axis of the tumour. Tumour size was measured at the 
level of the largest diameter. Specimens with nonpal-
pable tumours or mastectomies were sliced either from 
the nipple towards the pectoral wall or from medial to 
lateral. Tumour size was measured as the sum of slices 
containing tumour.
For the immunohistochemical (IHC) evaluation of 
ER, PR, HER2, and Ki-67 status, formalin-fixed, par-
affin-embedded tissue sections obtained from surgical 
specimens were stained with appropriate antibodies for 
ER (Novocastra, Newcastle upon Tyne, UK), PR (Novo-
castra), HER2 (Ventana Medical Systems, Tucson, AZ), 
and Ki-67 (MIB-1; Dako, Glostrup, Denmark). ER and PR 
were determined using nuclear staining, which was grad-
ed from 0 to 8 using the Allred score [19]. The results were 
categorised as positive when the total score, expressed as 
the sum of the proportion score and immunointensity 
score, was at least 3. For HER2 evaluation, membranous 
staining was graded as follows: scores of 0, 1, 2, and 3 [20]. 
HER2 status was deemed to be positive with a score of 3 
and negative with a score of 0 or 1. Tumours with a score 
of 2 were sent for fluorescence in situ hybridisation test-
ing, which was performed using the PathVysion HER2 
DNA Probe Kit (Abbott-Vysis, Des Plaines, IL). This test 
determines the HER2 amplification in the event that the 
ratio of the HER2 gene signal to chromosome 17 signal 
is more than 2, which is classified as positive. Ki-67 was 
reported as the percentage of immunoreactive cells among 
2000 tumour cells in randomly selected, high-power fields 
at the periphery of the tumour. Histological diagnoses 
were made by two pathologists with 10 and 15 years of 
experience in histological breast evaluation. 
Based on IHC or fluorescence in situ hybridisation 
findings of ER, PR, HER2, and Ki-67 expressions, the 
tumours were divided into four subtypes as per the rec-
ommendations of the 13th International Breast Cancer 
Conference held at St. Gallen, Switzerland in 2013 [21] 
as luminal A (ER and/or PR positive, Ki-67 ≤ 20%, HER2 
negative), luminal B (ER and/or PR positive, as well as Ki- 
67 > 20% or HER2 positive), HER2 positive (ER negative, 
PR negative, HER2 positive), and triple negative (ER neg-
ative, PR negative, HER2 negative). Tumours were divid-
ed into three histologic groups: invasive ductal carcino-
ma (IDC), invasive lobular carcinoma (ILC), and “other” 
(mucinous, tubular, microinvasive ductal carcinoma, and 
mixed cancers).
Statistical analysis
All statistical analyses were conducted using SPSS 20.0 
software (SPSS, Chicago, IL). We conducted a descrip-
tive analysis of all variables. Tumour sizes were compared 
using a paired t-test and Spearman’s Rho correlation 
analysis. Concordance rates between MRI and patholo-
gy according to histological subtype, molecular subtype, 
lymphovascular invasion, perineural invasion, histological 
grade, multiplicity, DCE-MRI characteristics, and ER, PR, 
and HER2 status were compared using the chi-squared 
test. After a positive chi-squared test (p < 0.05), multivar-
iate logistic regression analysis was performed, and the 
effects of factors were analysed using a backward stepwise 
logistic regression analysis. Dummy variables were used 
performing multiple comparisons of subgroups. P-values 
< 0.05 were considered statistically significant. 
Results
A total of 94 patients were included. The mean patient 
age was 52.2 years (age range, 30-78 years). The molec-
ular subtype distribution was luminal A, 51.1% (48/94); 
luminal B, 34% (32/94); HER2 positive 2.1% (2/94); and 
triple negative, 12.8% (12/94). Histopathological results 
revealed invasive ductal carcinoma (n = 82), invasive 
lobular carcinoma (n = 5), mucinous carcinoma (n = 3), 
tubular carcinoma (n = 1), mixed invasive ductal and lob-
ular carcinoma (n = 2), and microinvasive ductal carcino-
ma (n = 1). Table 1 shows all descriptives for discordant 
and concordant groups.
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Table 1. Descriptives for discordant and concordant groups
Factor Discordant Concordant Statistics
Tumours 22 (23.4%) 72 (76.6%)    
Age 53.3 (12.8) 51.9 (10.3) 0.521 0.604
Tumour size at MRI 3.6 (1.6) 2.5 (1) 4.095 < 0.001
Tumour size at pathology 3.1 (1.5) 2.5 (1) 2.299 0.024
Histologic subtype 0.161
IDK 18 64 4.157
ILK 3 2
Others 1 6
ER 0.733
Negative 4 10 0.245 
Positive 18 62
PR 0.595
Negative 8 20 0.594 
Positive 14 52
HER2 0.179
Negative 16 63 2.742
Positive 6 9
Ki67 0.463
≤ 20% 15 42 0.685 
> 20% 7 30
Molecular subtype 0.679
Luminal A 10 38 1.493
Luminal B 8 24
HER2 positive 0 2
Triple negative 4 8
Histological grade 0.193
1 0 9 3.294
2 17 49
3 3 14
LVI 0.328
Negative 11 45 1.093
Positive 11 27
PNI 0.755
Negative 19 59 0.233 
Positive 3 13
BPE 0.779
Minimal and mild 16 55 0.122 
Moderate and marked 6 17
FGV 0.899
Non-dense 12 35 0.711 
Dense 10 37
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The mean tumour size on MRI was 2.75 ± 1.22 cm. 
Tumour measurements determined by MRI were not sig-
nificantly different to those recorded in the pathological 
reports (2.64 ± 1.16 cm, Wilcoxon Z = –1.853, p = 0.064). 
Pearson correlation was 91.9% (Figure 1).
Tumour sizes were concordant in 72/94 patients 
(76.6%). MRI overestimated the size of 17/94 tumours 
(18.1%) with a mean overestimation of 0.47 ± 0.47 cm. 
MRI underestimated the size of 5/94 tumours (5.3%) with 
a mean underestimation of –0.29 ± 0.18 cm. The mean 
difference between the pathologic and MRI tumour sizes 
(Dm = pathology tumour size – MR size) was –0.1 cm, 
and this value ranged from –1 to 2.4 cm. 
There was no difference in tumour stage by MRI and 
pathological assessment in 84 of the 94 tumours (89.4%). 
The T stages of 10 patients were changed. The changes 
were seen at T1-T2. Of the 10 patients whose T stages 
changed, seven (7.4%) upstaged and three (3.2%) under-
staged with MRI. A comparison of the clinicohistologic 
characteristics affecting MRI-pathology concordance of 
tumour size and MRI-pathology discordance of tumour 
size are shown in Table 1.
MRI-pathology discordance was associated with larger 
tumour size. Both of the tumour size measurements esti-
mated from MRI and pathology reports had been affected 
Factor Discordant Concordant Statistics
Shape 0.125
Oval 10 24 4.419
Round 3 27
Irregular 9 21
Margin 0.035
Circumscribed 4 18 6.611
Irregular 16 31
Spiculated 2 23
Internal enhancement characteristics 0.006
Homogeneous 9 51 10.401
Heterogeneous 12 14
Rim enhancement 1 7
Dark internal septations 0 0
Morphology 0.136
Mass 20 71 3.235
Non-mass enhancement 2 1
Kinetic curve assessment  0.982
Persistent 4 7 2.15
Plateau 7 27
Washout 11 38
IDC – invasive ductal carcinoma, ILC – invasive lobular carcinoma, LVI – lymphovascular invasion, PNI – perineural invasion, ER – oestrogen receptor, PR – progesterone receptor, HER2 – human 
epidermal growth factor receptor 2
Table 1. Cont.
Figure 1. Tumour size measurements at pathology and dynamic con-
trast-enhanced magnetic resonance imaging (cm)
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in the same way (p < 0.001 for MRI size; p = 0.024 for 
pathological size) (Figure 2).
In ROC analyses (AUC: 0.752) 2.05 cm size estimat-
ed from MRI had a sensitivity of 81.8% and specificity 
of 34.7%. Taking the threshold to 3.4 cm, the sensitivity 
decreased to 54.5%, with increasing specificity to 87.5% 
(Figure 3).
On univariate analysis, the histological and molecular 
type of tumours were not associated with MRI-pathology 
concordance of tumour size. Also, measurement accura-
cies were not significantly affected by patient age, histo-
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logical grade, or lymphovascular invasion (LVI) or per-
ineural invasion (PNI) positivity. FGV and BPE did not 
differ between the discordant and the concordant group 
statistically. 
Table 1 also shows the comparison of BI-RADS de-
scriptors. MRI features of margin and internal enhance-
ment characteristics were statistically different between 
discordance and concordance groups. Irregular margin 
and heterogenous enhancement were associated with 
discordance in logistic regression analysis (p = 0.035, OR: 
4,24; p = 0.021, OR: 4.96) (Table 2). Ninety-one tumours 
(96.8%) with a mass enhancement and three tumours 
(3.2%) with a non-mass enhancement were found. Two of 
the three non-mass tumours were in the discordant group 
with lobular morphology. One triple-negative tumour, be-
longing to concordant group, was seen as non-mass en-
hancement. Features of being a mass or a non-mass en-
hancement did not significantly affect the discrepancies 
between MRI and pathological measurements of tumour 
size.
Discussion 
In the present study, we found excellent correlation be-
tween tumour size determined by MRI and the patholog-
ical reports; nonetheless, our overestimation rates were 
higher (18.1%) than underestimations (5.3%). Published 
studies assessing MRI-pathology concordance ranged 
from an underestimation rate of 0% to 59% to an overesti-
mation rate of 7% to 70% [22-25]. This wide range belongs 
to different concordance cut-off points, which was mostly 
agreed upon as ± 0.5 cm, as we accepted [5,12,26].
In a recent study by Yoo et al. in which strong cor-
relation was found between MRI and pathology meas-
urements, tumour size was overestimated in 11.7% and 
underestimated in 13.7% by MRI [13]. Patients with 
ductal carcinoma in situ (DCIS) were excluded from 
that study to avoid overestimations. The explanation for 
this was that pathological technicians could not measure 
the exact size of DCIS without using large-format histo-
pathology methods, which means pathology underesti-
mates DCIS size in today’s standard [27]. However, with 
the same exclusion, our overestimation rate was higher 
than the rate of underestimation, but our mean differ-
ence in tumour size was 0.1 cm, which corresponded to 
a nonsignificant size overestimation by MRI. Onesti et 
al. described a 1.06 cm overestimation with MRI in their 
series, especially for results for tumours larger than 2 cm 
in size, which is attributed the tumours with large DCIS 
components [12].
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Figure 2. Tumour size measurements at dynamic contrast-enhanced mag-
netic resonance imaging (MRI) in concordant and discordant groups
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Figure 3. Receiver operating characteristic (ROC) curve of the size assess-
ment of dynamic contrast-enhanced magnetic resonance imaging
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Table 2. Multivariate logistic regression analysis of possible factors affecting 
MRI-pathology concordance
Factor   p Odds
ratio
95% CI for EXP(B)
Lower Upper
Grade 3 0.112 0.262 0.050 1.364
Tumour size at MRI 0.081 1.684 0.938 3.024
Irregular margin 0.035 4.237 1.106 16.227
Heterogenic contrast  
enhancement
0.021 4.964 1.267 19.443
Constant 0.011 0.040    
χ2 = 23.646 p < 0.001 Cox & Snell R-kare = 0.227
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It was also found that while tumour size increases, 
concordance rates are becoming higher, as most of the 
studies concluded [5,12,13]. In our study, by ROC anal-
ysis, two thresholds were chosen for MRI accuracy of 
tumour size. When it was defined as 2.05 cm, the sen-
sitivity was highest; 81.8% of discordant measurements 
were above that cut-off. When the threshold of 3.4 cm 
was used, specificity was highest, and 87.5% of concordant 
measurements were below it. Previous literature mentions 
the 2 cm threshold and that DCE-MRI provides accurate 
estimations of tumour size ≤ 2 cm [5,14].
There is no consensus in the literature about the re-
lationship between accuracy of tumour size assessments 
and immunohistochemical types of breast cancer. Choi et 
al. studied the accuracy of MRI in breast cancer size as-
sessment with histopathological factors, with the biggest 
group in the literature [14]. They analysed the size of 808 
tumours and found that the size of tumours with positive 
ER receptor, negative HER2, luminal A type, nuclear and 
histological grade 1, negative nodal status, and negative 
LVI were significantly more accurately estimated. 
Additionally, Yoo et al. found that ER negativity was 
associated with MRI-pathology discordance. They ex-
plained that ER-negative tumours are larger at the time 
of diagnosis and present as non-mass enhancement more 
frequently than ER-positive tumours [28]. 
Nevertheless, we did not find any relation between 
histological and molecular type of tumours and size. LVI, 
PNI, and tumour grade did not differ statistically between 
the concordance and discordance groups [5,12].
To the best of our knowledge, previous studies inves-
tigated the effect of BI-RADS descriptors on size accuracy 
and did not find any statistical difference related to the BI-
RADS [13,28]. Our key finding was that BI-RADS descrip-
tors of heterogenous contrast uptake and irregular margin 
were statistically different between the discordant and the 
concordant group. New to the literature, we attributed the 
size discrepancy to morphologic specialities rather than 
molecular biology, even though morphologic differences 
come from molecular subtypes. We achieved this result by 
regression analyses of all variables in the present study.
In a recent study by Rawashdeh et al., nine expert 
breast radiologists (min 2000 mammograms per year, min-
imum 10 years) were asked to delineate the breast masses 
manually from mammograms by using the tablets. Even 
being experts, a fair to moderate level of agreement was 
found between radiologists for shape and margin assess-
ments using BI-RADS descriptors [29], which are qualita-
tive and demonstrate wide intra- and interobserver vari-
ations [10,30,31]. The aforementioned study supports our 
result that reliability of size assessment might come from 
morphological features of the tumour, which are described 
with qualitative BI-RADS MRI descriptors. 
In our study 75.5% of patients had minimal/mild 
BPE, whereas only 24.5% had moderate/marked BPE. 
Similarly, BPE levels in the high-BPE group are occasion-
ally lower than the BPE levels in the low BPE group in the 
studies about this subject [32-34]. We analysed the effect 
of BPE on size assessment, contrary to the literature, even 
with similar BPE ratios, and no statistical difference was 
found between the high and low BPE groups. However, 
it was shown that high BPE causes overestimation or un-
derestimation of tumour size by obscuring the margin of 
tumour [35].
Nevertheless, non-mass enhancement, which is de-
scribed as one of the main reasons for size discrepancy in 
most of the studies about this subject [11,13,35,36], was 
found to be ineffective in the present study. In the afore-
mentioned studies, it was thought that the size of non-
mass-enhanced lesions was difficult to measure because 
it is hard to determine the borders of the lesion, and so it 
may be difficult to differentiate from BPE, leading to in-
accurate measurements. In our study only three tumours 
were presented as non-mass enhancement, which may be 
the reason for our incompatible results with the literature. 
The measurements of maximum tumour size were tak-
en by using early-subtracted DCE T1-weighted sequence 
and MIP images in previous studies [2,4,11-14]. Naggara 
et al. investigated the value of MRI sequences for predic-
tion of breast tumour size and concluded that T2-weight-
ed images were better than DCE T1-weighted sequenc-
es. They gave a lot of attention to T2-weighted images, 
which do not overestimate the index tumour size. They 
also emphasised that late DCE T1-weighted images were 
frequently not found to be reliable enough to evaluate 
size, and they overestimated pathological size [37]. In our 
study we used the early-subtracted series, similarly to the 
literature. Our T2-weighted images are routinely fat sat-
urated, which is different from the aforementioned study, 
which found non-fat saturated T2-weighted sequence to 
be more reliable for tumour size analysis.
Limitation
Two pathologists and two radiologists from the same 
hospital studied the cases. We could not assess intraob-
server agreement between pathologists because of the 
retrospective design of the study. Also, we did not assess 
intraobserver agreement between radiologists because of 
time constraints. We analysed the cases in accordance. 
Although excellent correlation was found in MRI-pa-
thology concordance of tumour size measurements, two 
BI-RADS descriptors of irregular contour and heteroge-
neous contrast uptake were associated with discordancy. 
New to the literature, the discordancy might be attributed 
to the dynamic and morphological specialities of tumours 
primarily rather than tumour biology. A large-scale, pro-
spective study could provide more accurate findings.
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